To achieve an affordable price for its advanced cancer test, Delphi prioritizes algorithmic complexity over "wet lab" complexity. This strategy keeps physical sample processing simple and low-cost, putting the innovation into scalable software (AI/ML) to analyze the data, which is key for mass adoption.

AI's most significant impact won't be on broad population health management, but as a diagnostic and decision-support assistant for physicians. By analyzing an individual patient's risks and co-morbidities, AI can empower doctors to make better, earlier diagnoses, addressing the core problem of physicians lacking time for deep patient analysis.

The high cost of bringing an AI model to market ($5-10M) limits adoption to elite hospitals. By reducing validation costs 100x (to $50-100k), innovators can lower prices, making AI accessible to all hospitals and creating a viable ROI.

The immense regulatory complexity in U.S. healthcare creates an estimated $500 billion "tax" of administrative bloat. The non-obvious opportunity is that by using AI to eliminate this waste, the savings could be redirected to fund expanded patient care, rather than just being captured as profit.

To evaluate an AI model, first define the business risk. Use precision when a false positive is costly (e.g., approving a faulty part). Use recall when a false negative is costly (e.g., missing a cancer diagnosis). The technical metric must align with the specific cost of being wrong.

In rare diseases with small patient pools, recruiting for clinical trials is a major challenge. Effion Health's highly sensitive digital biomarkers can detect therapeutic efficacy with fewer participants, potentially reducing the required number of patients by 30%, which saves significant time and money for pharmaceutical companies.

A traditional IT investment ROI model misses the true value of AI in pharma. A proper methodology must account for operational efficiencies (e.g., time saved in clinical trials, where each day costs millions) and intangible benefits like improved data quality, competitive advantage, and institutional learning.

AI is improving medical imaging accuracy and speed by nearly 70%, enabling earlier detection of chronic diseases. This leads to more effective preventive care, which is crucial for an aging global population and offers a promising path to making overall healthcare more cost-effective.

George Church calculates that spending ~$100 to sequence a citizen's genome yields a $10k-$100k return. This massive ROI comes from avoiding the ~$1 million lifetime cost of caring for the 3% of children born with severe Mendelian diseases, a benefit realized within two years.